Larimar Therapeutics, Inc.
LRMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44,931 | $23,368 | $26,552 | $26,738 |
| G&A Expenses | $4,568 | $4,424 | $4,636 | $4,555 |
| SG&A Expenses | $4,668 | $4,424 | $4,636 | $4,555 |
| Sales & Mktg Exp. | $100 | $0 | $0 | $0 |
| Other Operating Expenses | -$100 | $0 | $0 | $0 |
| Operating Expenses | $49,499 | $27,792 | $31,188 | $31,293 |
| Operating Income | -$49,499 | -$27,792 | -$31,188 | -$31,293 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,787 | $1,610 | $1,907 | $2,469 |
| Pre-Tax Income | -$47,712 | -$26,182 | -$29,281 | -$28,824 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$47,712 | -$26,182 | -$29,281 | -$28,824 |
| % Margin | – | – | – | – |
| EPS | -0.61 | -0.41 | -0.46 | -0.45 |
| % Growth | -48.8% | 10.9% | -2.2% | – |
| EPS Diluted | -0.61 | -0.41 | -0.46 | -0.45 |
| Weighted Avg Shares Out | 78,325 | 64,028 | 63,964 | 63,811 |
| Weighted Avg Shares Out Dil | 78,325 | 64,028 | 63,964 | 63,811 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $88 | $87 | $88 | $77 |
| EBITDA | -$47,624 | -$27,705 | -$31,100 | -$31,216 |
| % Margin | – | – | – | – |